Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20


Anti-HER2 scFv-directed extracellular vesicle-mediated mRNA-based gene delivery inhibits growth of HER2-positive human breast tumor xenografts by prodrug activation.

Wang JH, Forterre AV, Zhao J, Frimannsson DO, Delcayre A, Antes TJ, Efron B, Jeffrey SS, Pegram MD, Matin AC.

Mol Cancer Ther. 2018 Feb 26. pii: molcanther.0827.2017. doi: 10.1158/1535-7163.MCT-17-0827. [Epub ahead of print]


Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.

Foy SP, Mandl SJ, dela Cruz T, Cote JJ, Gordon EJ, Trent E, Delcayre A, Breitmeyer J, Franzusoff A, Rountree RB.

Cancer Immunol Immunother. 2016 May;65(5):537-49. doi: 10.1007/s00262-016-1816-7. Epub 2016 Mar 10.


Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy.

Mandl SJ, Rountree RB, Dela Cruz TB, Foy SP, Cote JJ, Gordon EJ, Trent E, Delcayre A, Franzusoff A.

J Immunother Cancer. 2014 Oct 14;2(1):34. doi: 10.1186/s40425-014-0034-0. eCollection 2014.


Increasing vaccine potency through exosome antigen targeting.

Hartman ZC, Wei J, Glass OK, Guo H, Lei G, Yang XY, Osada T, Hobeika A, Delcayre A, Le Pecq JB, Morse MA, Clay TM, Lyerly HK.

Vaccine. 2011 Nov 21;29(50):9361-7. doi: 10.1016/j.vaccine.2011.09.133. Epub 2011 Oct 12.


Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells.

Mandl SJ, Rountree RB, Dalpozzo K, Do L, Lombardo JR, Schoonmaker PL, Dirmeier U, Steigerwald R, Giffon T, Laus R, Delcayre A.

Cancer Immunol Immunother. 2012 Jan;61(1):19-29. doi: 10.1007/s00262-011-1077-4. Epub 2011 Aug 7.


Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy.

Rountree RB, Mandl SJ, Nachtwey JM, Dalpozzo K, Do L, Lombardo JR, Schoonmaker PL, Brinkmann K, Dirmeier U, Laus R, Delcayre A.

Cancer Res. 2011 Aug 1;71(15):5235-44. doi: 10.1158/0008-5472.CAN-10-4076. Epub 2011 Jun 13.


A flow cytometry-based immuno-titration assay for rapid and accurate titer determination of modified vaccinia Ankara virus vectors.

Li Z, Ling L, Liu X, Laus R, Delcayre A.

J Virol Methods. 2010 Oct;169(1):87-94. doi: 10.1016/j.jviromet.2010.07.003. Epub 2010 Jul 14.


Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses.

Zeelenberg IS, Ostrowski M, Krumeich S, Bobrie A, Jancic C, Boissonnas A, Delcayre A, Le Pecq JB, Combadière B, Amigorena S, Théry C.

Cancer Res. 2008 Feb 15;68(4):1228-35. doi: 10.1158/0008-5472.CAN-07-3163.


Exosome nanovesicles displaying G protein-coupled receptors for drug discovery.

Estelles A, Sperinde J, Roulon T, Aguilar B, Bonner C, LePecq JB, Delcayre A.

Int J Nanomedicine. 2007;2(4):751-60.


Exosomes as novel therapeutic nanodevices.

Delcayre A, Le Pecq JB.

Curr Opin Mol Ther. 2006 Feb;8(1):31-8. Review.


Exosome Display technology: applications to the development of new diagnostics and therapeutics.

Delcayre A, Estelles A, Sperinde J, Roulon T, Paz P, Aguilar B, Villanueva J, Khine S, Le Pecq JB.

Blood Cells Mol Dis. 2005 Sep-Oct;35(2):158-68.


Dendritic cell-derived exosomes in cancer immunotherapy: exploiting nature's antigen delivery pathway.

Delcayre A, Shu H, Le Pecq JB.

Expert Rev Anticancer Ther. 2005 Jun;5(3):537-47. Review.


Lactadherin promotes VEGF-dependent neovascularization.

Silvestre JS, Théry C, Hamard G, Boddaert J, Aguilar B, Delcayre A, Houbron C, Tamarat R, Blanc-Brude O, Heeneman S, Clergue M, Duriez M, Merval R, Lévy B, Tedgui A, Amigorena S, Mallat Z.

Nat Med. 2005 May;11(5):499-506. Epub 2005 Apr 17.


A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer.

Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A, Hsu DH, Le Pecq JB, Lyerly HK.

J Transl Med. 2005 Feb 21;3(1):9.


A genome-based functional screening approach to vaccine development that combines in vitro assays and DNA immunization.

Delcayre A, Peake JS, White DJ, Yuan S, McDonald MK, Liang A, Tan PL, Watson JD.

Vaccine. 2003 Jul 4;21(23):3259-64.


Epstein Barr virus/complement C3d receptor is an interferon alpha receptor.

Delcayre AX, Salas F, Mathur S, Kovats K, Lotz M, Lernhardt W.

EMBO J. 1991 Apr;10(4):919-26.


Supplemental Content

Loading ...
Support Center